Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SBT 101

Drug Profile

SBT 101

Alternative Names: AAV9-ABCD1; AAV9-hABCD1; SBT-101 - SwanBio Therapeutics; SBT101

Latest Information Update: 20 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator SwanBio Therapeutics
  • Class Adrenoleucodystrophy gene therapies; Gene therapies
  • Mechanism of Action ALDP expression stimulants; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Adrenomyeloneuropathy
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Adrenomyeloneuropathy

Most Recent Events

  • 17 Jun 2024 SwanBio Therapeutics has been acquired by Spur Therapeutics
  • 04 Oct 2023 SBT 101 receives Orphan Drug status for Adrenomyeloneuropathy in European Union, prior to October 2023
  • 04 Oct 2023 SwanBio Therapeutics announces approval of its Clinical Trial Application (CTA) from the Central Committee on Research Involving Human Subjects (CCMO) for SBT 101 in Netherlands, prior to October 2023
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top